Last reviewed · How we verify
NCT05041673
Anti-diabetic Drugs and Fatty Liver Management
NA trial testing Metformin in Fatty Liver, Nonalcoholic in 120 participants. Status unknown.
30 September 2021
Quick facts
| Lead sponsor | Alexandria University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 23 February 2021 |
| Primary completion | 30 September 2021 |
| Estimated completion | 30 September 2022 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Metformin (metformin) — full drug profile →
Conditions studied
- Fatty Liver, Nonalcoholic — all drugs for Fatty Liver, Nonalcoholic →
- Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →
Sponsor
Alexandria University
Who can join
18 and older, any sex, with Fatty Liver, Nonalcoholic or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Type 2 DM is one of the major risk factors for development of non-alcoholic fatty liver disease. The pooled prevalence of fatty liver among diabetics is 54% (95% CI 45%-64%). Until now there is no well-established treatment for fatty liver disease. Study setting: Randomized controlled trial Study population: Patients with type 2 DM plus Fatty Liver. Arms and Interventions 1\. Experimental arms: Group 1: metformin +/- insulin +/- sulfonylurea Group 2: Metformin plus vildagliptin+/- insulin +/- sulfonylurea Group 3: Metformin plus liraglutide+/- insulin+/- sulfonylurea Group 4: Metformin plus empagliflozin +/- insulin +/- sulfonylurea
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Mitochondrial Quality Control: Its Role in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).
Shin S, Kim J, Lee JY, Kim J, et al · · 2023 · cited 45× · PMID 38049180 · DOI 10.7570/jomes23054 -
Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD.
Vitulo M, Gnodi E, Rosini G, Meneveri R, et al · · 2023 · cited 21× · PMID 37628929 · DOI 10.3390/ijms241612748 -
The Roles of Myeloid Cells in Aging-related Liver Diseases.
Yao J, Li Y, Wang H. · · 2023 · cited 9× · PMID 37056921 · DOI 10.7150/ijbs.82352 -
Hepatic Mechanisms of Myocardial Infarction: A New Perspective in Metabolic Dysfunction-Associated Fatty Liver Disease.
Cui J, Wang W, Xu Q, Zhu M, et al · · 2025 · PMID 40879000 · DOI 10.1161/jaha.124.040775
Verify or expand the search:
- PubMed search for NCT05041673
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Metformin
Trials testing the same drug.
- NCT07275359 — Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations · Phase 1 · not yet recruiting
- NCT07520110 — Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07007221 — Clinical Trials to Evaluate Metformin to Treat Depression in People Living With HIV · Phase 2 · not yet recruiting
- NCT07585396 — Inositol in Letrozol Resistant PCOS Women · Phase 2, PHASE3 · not yet recruiting
- NCT07226453 — Target Validation and Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Ependymoma · Phase 2 · not yet recruiting
Other recruiting trials for Fatty Liver, Nonalcoholic
Currently open trials in the same condition.
- NCT06596109 — Lifestyle Changes in Fatty Liver; Additive Effect of Honey Intake · NA · recruiting
- NCT06503120 — Nutritional Education Program for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) · NA · active not recruiting
- NCT06321211 — Development of a Novel Asian Mediterranean Diet and Its Acceptability in NAFLD · active not recruiting
- NCT06445361 — Prevalence of NAFLD in T1DM Patients · NA · recruiting
- NCT05855239 — Quantification of Hepatic Steatosis With Different Ultrasound Frequency · active not recruiting
Other Alexandria University trials
Trials by the same sponsor.
- NCT07517861 — Integrated Mental Health Nursing Program: Effects on Stigma, Cognitive Flexibility, and Clinical Readiness · NA · recruiting
- NCT07476482 — The Impact of a Shared Decision-Making Intervention on Intraoperative Patient Experience During Elective Cesarean Delive · NA · enrolling by invitation
- NCT07476209 — Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia · NA · recruiting
- NCT07503626 — Optimization of Orthodontic Bracket Placement by Using Two Different Protocols of Digitally Aided Bonding · NA · recruiting
- NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05041673 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alexandria University
- Last refreshed: 18 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05041673.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing